$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

$snoa Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000168316824005371 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$3.579M	$3.391M	$3.427M
YoY Change	31.05%	-1.05%	-13.96%
Cost Of Revenue	$2.218M	$2.085M	$2.223M
YoY Change	27.4%	-6.21%	-12.38%
Gross Profit	$1.361M	$1.306M	$1.204M
YoY Change	37.47%	8.47%	-16.74%
Gross Profit Margin	38.03%	38.51%	35.13%
Selling, General & Admin	$1.705M	$2.009M	$2.119M
YoY Change	2.59%	-5.19%	-7.67%
% of Gross Profit	125.28%	153.83%	176.0%
Research & Development	$506.0K	$470.0K	$325.0K
YoY Change	-5.6%	44.62%	5316.67%
% of Gross Profit	37.18%	35.99%	26.99%
Depreciation & Amortization	$35.00K	$39.00K	$45.00K
YoY Change	-12.5%	-13.33%	45.16%
% of Gross Profit	2.57%	2.99%	3.74%
Operating Expenses	$2.211M	$2.479M	$2.444M
YoY Change	0.59%	1.43%	6.21%
Operating Profit	-$850.0K	-$1.173M	-$1.240M
YoY Change	-29.64%	-5.4%	45.03%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$387.0K	$176.0K	-$211.0K
YoY Change	-530.0%	-183.41%	214.93%
Pretax Income	-$463.0K	-$997.0K	-$1.451M
YoY Change	-64.33%	-31.29%	57.38%
Income Tax	$147.0K	$146.0K	-$33.00K
% Of Pretax Income
Net Earnings	-$610.0K	-$1.143M	-$1.418M
YoY Change	-58.89%	-19.39%	59.86%
Net Earnings / Revenue	-17.04%	-33.71%	-41.38%
Basic Earnings Per Share	-$0.59	-$0.07	-$0.29
Diluted Earnings Per Share	-$0.59	-$0.07	-$0.29
COMMON SHARES
Basic Shares Outstanding	19.15M shares	18.77M shares	4.942M shares
Diluted Shares Outstanding	1.034M shares	17.03M shares	4.936K shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.078M	$2.589M	$3.544M
YoY Change	90.56%	-26.95%	-36.56%
Cash & Equivalents	$4.078M	$2.589M	$3.544M
Short-Term Investments
Other Short-Term Assets	$2.149M	$3.433M	$4.874M
YoY Change	-53.78%	-29.57%	21.58%
Inventory	$2.837M	$2.658M	$2.730M
Prepaid Expenses
Receivables	$3.157M	$3.247M	$2.439M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.22M	$11.93M	$13.59M
YoY Change	6.12%	-12.22%	-8.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$255.0K	$302.0K	$485.0K
YoY Change	-41.11%	-37.73%	56.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$76.00K	$61.00K	$77.00K
YoY Change	1.33%	-20.78%	-31.25%
Total Long-Term Assets	$1.464M	$1.746M	$2.306M
YoY Change	-30.91%	-24.28%	-1.5%
TOTAL ASSETS
Total Short-Term Assets	$12.22M	$11.93M	$13.59M
Total Long-Term Assets	$1.464M	$1.746M	$2.306M
Total Assets	$13.69M	$13.67M	$15.89M
YoY Change	0.37%	-13.97%	-7.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$770.0K	$751.0K	$1.090M
YoY Change	-21.99%	-31.1%	-47.01%
Accrued Expenses	$2.138M	$2.383M	$2.488M
YoY Change	11.35%	-4.22%	13.87%
Deferred Revenue
YoY Change
Short-Term Debt	$82.00K	$204.0K	$301.0K
YoY Change	-51.76%	-32.23%	-34.42%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.309M	$3.751M	$4.041M
YoY Change	2.16%	-7.18%	-16.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$5.024M	$4.947M	$4.610M
YoY Change	6.44%	7.31%	6.47%
Total Long-Term Liabilities	$5.024M	$4.947M	$4.610M
YoY Change	6.44%	7.31%	30633.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.309M	$3.751M	$4.041M
Total Long-Term Liabilities	$5.024M	$4.947M	$4.610M
Total Liabilities	$8.333M	$8.698M	$8.651M
YoY Change	4.69%	0.54%	-5.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$196.1M	-$195.5M	-$190.9M
YoY Change	1.92%	2.39%	3.07%
Common Stock	$205.7M	$204.1M	$201.1M
YoY Change	2.21%	1.49%	1.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.352M	$4.975M	$7.242M
YoY Change
Total Liabilities & Shareholders Equity	$13.69M	$13.67M	$15.89M
YoY Change	0.37%	-13.97%	-7.37%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$610.0K	-$1.143M	-$1.418M
YoY Change	-58.89%	-19.39%	59.86%
Depreciation, Depletion And Amortization	$35.00K	$39.00K	$45.00K
YoY Change	-12.5%	-13.33%	45.16%
Cash From Operating Activities	$354.0K	-$912.0K	-$215.0K
YoY Change	-128.78%	324.19%	-85.98%
INVESTING ACTIVITIES
Capital Expenditures	$26.00K	$5.000K	$17.00K
YoY Change		-70.59%	-26.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$26.00K	-$5.000K	-$17.00K
YoY Change		-70.59%	-26.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.444M	$636.0K	-$135.0K
YoY Change	-1303.33%	-571.11%	-65.12%
NET CHANGE
Cash From Operating Activities	354.0K	-$912.0K	-$215.0K
Cash From Investing Activities	-26.00K	-$5.000K	-$17.00K
Cash From Financing Activities	1.444M	$636.0K	-$135.0K
Net Change In Cash	1.772M	-$539.0K	-$276.0K
YoY Change	-231.26%	95.29%	-84.75%
FREE CASH FLOW
Cash From Operating Activities	$354.0K	-$912.0K	-$215.0K
Capital Expenditures	$26.00K	$5.000K	$17.00K
Free Cash Flow	$328.0K	-$917.0K	-$232.0K
YoY Change	-126.67%	295.26%	-85.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	dei	Entity File Number EntityFileNumber	001-33216
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	dei	Document Type DocumentType	10-Q
CY2024Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q2	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q2	dei	Entity Registrant Name EntityRegistrantName	SONOMA PHARMACEUTICALS, INC.
CY2024Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0423298
CY2024Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	5445 Conestoga Court
CY2024Q2	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
CY2024Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Boulder
CY2024Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2024Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80301
CY2024Q2	dei	City Area Code CityAreaCode	800
CY2024Q2	dei	Local Phone Number LocalPhoneNumber	759-9305
CY2024Q2	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2024Q2	dei	Trading Symbol TradingSymbol	SNOA
CY2024Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19149393	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3128000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2898000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2719000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3541000	usd
CY2024Q2	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	237000	usd
CY2024Q1	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	262000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	12548000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	365000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	286000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1145000	usd
CY2024Q2	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	246000	usd
CY2024Q1	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	330000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	66000	usd
CY2024Q1	us-gaap	Assets Assets	14740000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	607000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2113000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	478000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	323000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	198000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3719000	usd
CY2024Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	87000	usd
CY2024Q1	SNOA	Withholding Tax Payable WithholdingTaxPayable	4710000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	8603000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19004393	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19004393	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15607433	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15607433	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	203207000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194349000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2723000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6137000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14740000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2085000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	1306000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	1204000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	470000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	325000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2009000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2119000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	2479000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2444000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1173000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1240000	usd
CY2024Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	176000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-211000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-997000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1451000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	146000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1143000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17029000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17029000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4936000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4936000	shares
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-881000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	511000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2024000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-907000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1143000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45000	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	107000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	177000	usd
CY2024Q2	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-122000	usd
CY2023Q2	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-90000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-55000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-79000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	470000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-191000	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	114000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-230000	usd
CY2024Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-59000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	84000	usd
CY2024Q2	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	53000	usd
CY2023Q2	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	49000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	182000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	214000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	186000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	180000	usd
CY2024Q2	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	112000	usd
CY2023Q2	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	122000	usd
CY2024Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55000	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-79000	usd
CY2024Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-45000	usd
CY2023Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-912000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-215000	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	748000	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-5000	usd
CY2024Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q2	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	119000	usd
CY2023Q2	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	130000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	636000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-135000	usd
CY2024Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-258000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-539000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-276000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3128000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3820000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2589000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3544000	usd
CY2024Q2	us-gaap	Interest Paid Net InterestPaidNet	5000	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	5000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6137000	usd
CY2024Q2	SNOA	Proceeds From Atthemarket Sale Of Common Stock Net Of Offering Expenses ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpenses	748000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	107000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-881000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1143000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	4975000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7977000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-5000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	177000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	511000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7242000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1143000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195492000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-194349000	usd
CY2024Q2	SNOA	Working Capital WorkingCapital	8176000	usd
CY2024Q1	SNOA	Working Capital WorkingCapital	8829000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-912000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-215000	usd
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_z0puAck5vU17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zbeVtVSNTJPi">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1143000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17029000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17029000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4936000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4936000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	993000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	727000	shares
CY2024Q2	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	32000	usd
CY2024Q1	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	27000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	262000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	296000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1695000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1802000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1225000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1213000	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	2920000	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	3015000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	262000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	296000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2658000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2719000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	216000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	286000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	155000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	198000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	93000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	55000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0600	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	150000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	67000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	240000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	24000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	216000	usd
CY2024Q2	us-gaap	Officers Compensation OfficersCompensation	586000	usd
CY2024Q2	SNOA	Potential Severance Payments PotentialSeverancePayments	1300000	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	107000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	177000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1464	pure
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3391000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3427000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3391000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3427000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-005371-index-headers.html	Edgar Link	pending
0001683168-24-005371-index.html	Edgar Link	pending
0001683168-24-005371.txt	Edgar Link	pending
0001683168-24-005371-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snoa-20240630.xsd	Edgar Link	pending
sonoma_ex3101.htm	Edgar Link	pending
sonoma_ex3102.htm	Edgar Link	pending
sonoma_ex3201.htm	Edgar Link	pending
sonoma_i10q-063024.htm	Edgar Link	pending
snoa-20240630_def.xml	Edgar Link	unprocessable
snoa-20240630_lab.xml	Edgar Link	unprocessable
snoa-20240630_pre.xml	Edgar Link	unprocessable
sonoma_i10q-063024_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
snoa-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

2024 Q3 Form 10-Q Financial Statement

#000168316824005371 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA Sonoma Pharmaceuticals, Inc. Stock $snoa

2024 Q3 Form 10-Q Financial Statement

#000168316824005371 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa